Analysts’ Weekly Ratings Updates for Enliven Therapeutics (ELVN)

A number of research firms have changed their ratings and price targets for Enliven Therapeutics (NASDAQ: ELVN):

• 5/12/2026 – Enliven Therapeutics is now covered by Guggenheim. They set a “buy” rating and a $80.00 price target on the stock.
• 5/11/2026 – Enliven Therapeutics was upgraded by Guggenheim to “strong-buy”.
• 5/11/2026 – Enliven Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 5/8/2026 – Enliven Therapeutics had its price target raised by The Goldman Sachs Group, Inc. from $41.00 to $59.00. They now have a “buy” rating on the stock.
• 5/3/2026 – Enliven Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 4/25/2026 – Enliven Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 4/20/2026 – Enliven Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 3/26/2026 – Enliven Therapeutics had its price target raised by HC Wainwright from $48.00 to $56.00. They now have a “buy” rating on the stock.
• 3/25/2026 – Enliven Therapeutics had its price target raised by Mizuho from $41.00 to $45.00. They now have an “outperform” rating on the stock.

Insider Activity at Enliven Therapeutics

In related news, CFO Benjamin Hohl sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, March 6th. The shares were sold at an average price of $29.58, for a total transaction of $295,800.00. Following the completion of the sale, the chief financial officer owned 51,000 shares of the company’s stock, valued at $1,508,580. This trade represents a 16.39% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Richard A. Heyman sold 1,230 shares of the firm’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $26.18, for a total transaction of $32,201.40. Following the sale, the director directly owned 22,647 shares of the company’s stock, valued at $592,898.46. This trade represents a 5.15% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 25.90% of the stock is owned by company insiders.

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.